Eleven Biotherapeutics Raises $50M in IPO

Cambridge, MA-based biopharmaceutical company Eleven Biotherapeutics raised $50m in its IPO.

Eleven, which priced its offering of 5m shares at $10 per share, started trading the stock on February 6, 2014 on the NASDAQ under the ticker symbol “EBIO”.

Led by led by CEO Abbie Celniker, PhD, Eleven Biotherapeutics is a clinical-stage biopharmaceutical company with a proprietary protein engineering platform, called AMP-Rx, that it applies to the discovery and development of protein therapeutics to treat diseases of the eye.

Backers included Third Rock Ventures, Flagship Ventures and Jafco. Have a look at its deals:

08/05/2012: Eleven Biotherapeutics Raises $20M in Series A Equity Financing
17/02/2010: Eleven Biotherapeutics Completes $35M Series A Funding

FinSMEs

10/02/2014

Join the discussion